The effective role of hydroxyapatite- based composites in anticancer drug- delivery systems

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 33, Issue 1, 2016, Pages 41-75

  Saber Samandari, Samaneh ^a   Nezafati, Nader ^b   Saber Samandari, Saeed ^c  

^a EASTERN MEDITERRANEAN UNIVERSITY   (Turkey)

^b MATERIALS AND ENERGY RESEARCH CENTER   (Iran)

^c AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

Author keywords

Cancer; Chemotherapy; Composites; Drug delivery; Hydroxyapatite

Indexed keywords

ALGINIC ACID; ANTINEOPLASTIC AGENT; CALCIUM PHOSPHATE; CARBOPLATIN; CHITOSAN; CHONDROITIN SULFATE; CIPROFLOXACIN; CISPLATIN; COLLAGEN; CYCLODEXTRIN; GELATIN; HYDROXYAPATITE; METHOTREXATE; MOLECULAR SCAFFOLD; PENTOXIFYLLINE; POLYMER; POLYSULFONE; POLYURETHAN; VANCOMYCIN; BIOMATERIAL; DELAYED RELEASE FORMULATION; DRUG CARRIER;

ARTICLE; COMPOSITE; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; IMMUNE RESPONSE; INFRARED SPECTROSCOPY; MTT ASSAY; NONHUMAN; PH; POROSITY; SCANNING ELECTRON MICROSCOPY; SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; DELAYED RELEASE FORMULATION; NEOPLASMS; PARTICLE SIZE; SURFACE PROPERTY;

ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; HUMANS; HYDROXYAPATITES; NEOPLASMS; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 85013170721     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v33.i1.30     Document Type: Article

References (224)

1. Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances. J Control Release. 2014;194:238-56.
2. Nowell PC. The clonal evolution of tumour cell populations. Science. 1976;194:23-8.
3. Khan IU, Serra CA, Anton N, Vandamme T. Microfluidics: A focus on improved cancer targeted drug delivery systems. J Control Release. 2013;172:1065-74.
4. Jassem J. The role of radiotherapy in lung cancer: Where is the evidence? Radiother Oncol. 2007;83:203-13.
5. Bottke D, Wiegel T. Radiotherapy and prostate cancer: Quo Vadis? Eur Urol. 2010;9:394-9.
6. Kester M, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, Altinoglu EI, Tabakovic A, Parette MR, Rouse SM, Ruiz-Velasco V, Adair JH. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett. 2008;8:4116-21.
7. Tan ML, Choong PFM, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol. 2009;61:3-12.
8. Laurencin CT, Attawia MA, Lu LQ, Borden MD, Lu HH, Gorum WJ, Lieberman JR. Poly(lactideco- glycolide)/hydroxyapatite delivery of BMP-2-producing cells: A regional gene therapy approach to bone regeneration. Biomaterials. 2001;22:1271-7.
9. Li G, Ye L, Pan J, Long M, Zhao Z, Yang H, Tian J, Wen Y, Dong S, Guan J, Luo B. Antitumoural hydroxyapatite nanoparticles-mediated hepatoma-targeted trans-arterial embolization gene therapy: In vitro and in vivo studies. Liver Int. 2012;32:998-1007.
10. Ciocca DR, Frayssinet P, Cuello-Carrion FD. A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients. Cell Stress Chaperon. 2007;12:33-43.
11. Kaisary AV. Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. Prostate Cancer PD. 2005;8:140-51.
12. Keller ET, Dai JL, Escara-Wilke J, Hall CL, Ignatoski K, Taichman RS. New trends in the treatment of bone metastasis. J Cell Biochem. 2007;102:1095-102.
13. DeVita Jr VT, Hellman S, Rosenberg SA. Cancer: Principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
14. Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol. 1987;14:3-11.
15. Yim H, Park W, Kim D, Fahmy TM, Na K. A self-assembled polymeric micellar immunomodulator for cancer treatment based on cationic amphiphilic polymers. Biomaterials. 2014;35:9912-9.
16. Stuart MAC, Huck WTS, Genzer J, Müller M, Ober C, Stamm M, Sukhorukov GB, Szleifer I, Tsukruk VV, Urban M, Winnik F, Zauscher S, Luzinov I, Minko S. Emerging applications of stimuliresponsive polymer materials. Nature Mater. 2010;9:101-13.
17. Backles R. Biomaterials for drug delivery systems. J Biomed Mater Res. 1983;17:109-28.
18. Bajpai PK, Benghuzzi HA. Ceramic systems for long-term delivery of chemicals and biologicals. J Biomed Mater Res. 1988;22:1245-66.
19. Barroug A, Glimcher MJ. Hydroxyapatite crystals as a local drug delivery system for cisplatin: Adsorption and release of cisplatin in vitro. J Orthop Res. 2002;20:274-80.
20. Betsiou M, Bantsis G, Zoi I, Sikalidis C. Adsorption and release of gemcitabine hydrochloride and oxaliplatin by hydroxyapatite. Ceram Int. 2012;38:2719-24.
21. Downes S, Clifford CJ, Scotchford C, Klein CP. Comparison of the release of growth hormone from hydroxyapatite, heat-treated hydroxyapatite, and fluoroapatite coatings on titanium. J Biomed Mater Res. 1995;29:1053-60.
22. Guicheux J, Grimandi G, Trecant M, Faivre A, Daculsi G, Takahashi S. Apatite as carrier for growth hormone: In vitro characterization of loading and release. J Biomed Mater Res. 1997;34:165-70.
23. Ensign LM, Cone R, Hanes J. Nanoparticle-based drug delivery to the vagina: A review. J Control Release. 2014;190:500-14.
24. Takagi O, Kuramoto N, Ozawa M, Suzuki S. Adsorption/desorption of acidic and basic proteins on needle-like hydroxyapatite filter prepared by slip casting. Ceram Int. 2004;30:139-43.
25. Matsumoto T, Okazaki M, Inoue M, Yamaguchi S, Kusunose T, Toyonaga T, Hamada Y, Takahashi J. Hydroxyapatite particles as a controlled release carrier of protein. Biomaterials. 2004;25:3807-12.
26. Tomoda K, Ariizumi H, Nakaji T, Makino K. Hydroxyapatite particles as drug carriers for proteins. Colloids Surf B Biointerfaces. 2010;76:226-35.
27. Chai F, Hornez JC, Blanchemain N, Neut C, Descamps M, Hildebrand HF. Antibacterial activation of hydroxyapatite (HA) with controlled porosity by different antibiotics. Biomol Eng. 2007;24:510-4.
28. Hasegawa M, Sudo A, Komlev VS, Barinov SM, Uchida A. High release of antibiotic from a novel hydroxyapatite with bimodal pore size distribution. J Biomed Mater Res Part B: Appl Biomater. 2004;70:332-9.
29. Rauschmann MA, Wichelhaus TA, Stirnal V, Dingeldein E, Zichner L, Schnettler R, Alt V. Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections. Biomaterials. 2005;26:2677-84.
30. Otsuka M, Matsuda Y, Suwa Y, Fox JL, Higuchi WI. A novel skeletal drug-delivery system using self-setting calcium phosphate cement. 3. Physicochemical properties and drug-release rate of bovine insulin and bovine albumin. J Pharm Sci. 1994;83:255-8.
31. Bisht S, Bhakta G, Mitra S, Maitra A. pDNA loaded calcium phosphate nanoparticles: Highly efficient non-viral vector for gene delivery. Int J Pharm. 2005;288:157-68.
32. Lebugle A, Rodrigues A, Bonnevialle P, Voigt JJ, Canal P, Rodriguez F. Study of implantable calcium phosphate systems for the slow release of methotrexate. Biomaterials. 2002;23:3517-22.
33. Uchida A, Shinto Y, Araki N, Ono K. Slow release of anticancer drugs from porous calcium hydroxyapatite ceramic. J Orthop Res. 1992;10:440-5.
34. Adlakha-Hutcheon G, Bally MB, Shew CF, Madden TD. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nature Biotechnol. 1999;17: 775-9.
35. Mikhail AS, Allen C. Block copolymer micelles for delivery of cancer therapy: Transport at the whole body, tissue and cellular levels. J Control Release. 2009;138:214-23.
36. Itokazu M, Sugiyama T, Ohno T, Wada E, Katagiri Y. Development of porous apatite ceramic for local delivery of chemotherapeutic agents. J Biomed Mater Res. 1998;39:536-8.
37. Burgos AE, Belchior JC, Sinisterra RD. Controlled release of rhodium (II) carboxylates and their association complexes with cyclodextrins from hydroxyapatite matrix. Biomaterials. 2002;23:2519-26.
38. Kunieda K, Seki T, Nakatani S, Wakabayashi M, Shiro T, Inoue K, Sougawa M, Kimura R, Harada K. Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer. Br J Cancer. 1993;67: 668-73.
39. Wang H, Li Y, Zuo Y, Li J, Ma S, Cheng L. Biocompatibility and osteogenisis of biomimetic nanohydroxyapatite/ polyamide composite scaffold for bone tissue engineering. Biomaterials. 2007;28: 3338-48.
40. Itokazu M, Yang W, Aoki T, Ohara A, Kato N. Synthesis of antibiotic-loaded interporous hydroxyapatite blocks by vacuum method and in vitro drug release testing. Biomaterials. 1998;19:817-9.
41. Olton D, Li J, Wilson ME, Rogers T, Close J, Huang L. Nanostructured calcium phosphates (Nano- CaPs) for non-viral gene delivery: Influence of the synthesis parameters on transfection efficiency. Biomaterials. 2007;28:1267-79.
42. Wang S, McDonnell EH, Sedor FA, Toffaletti JG. PH effects on measurements of ionized calcium and ionized magnesium in blood. Arch Pathol Lab Med. 2002;126:947-50.
43. Chinol M, Vallabhajosula S, Goldsmith SJ. Chemistry and biological behavior of samarium-153 and rhenium-186-labeled hydroxyapatite particles: Potential radiopharmaceuticals for radiation synovectomy. J Nucl Med. 1993;34:1536-43.
44. Unni PR, Chaudhari PR, Venkatesh M. Preparation and bioevaluation of 166Ho labeled hydroxyapatite (HA) particles for radiosynovectomy. Nucl Med Biol. 2002;29:199-205.
45. Kundu B, Ghosh D, Sen S, Ballaa VK, Das N, Basua D. Doxorubicin-intercalated nano-hydroxyapatite drug-delivery system for liver cancer: An animal model. Ceram Int. 2013;39:9557-66.
46. Yin MZ, Han YC, Bauer IW, Chen P, Li SP. Effect of hydroxyapatite nanoparticles on the ultrastructure and function of hepatocellular carcinoma cells in vitro. Biomed Mater. 2006;1:38-41.
47. Bauer IW, Li SP, Han YC, Yuan L, Yin MZ. Internalization of hydroxyapatite nanoparticles in liver cancer cells. J Mater Sci: Mater Med. 2008;19:1091-5.
48. Morgan MP, Cooke MM, McCarthy GM, Christopherson PA, Westfall PR, McCarthy GM. Calcium hydroxyapatite promotes mitogenesis and matrix metalloproteinase expression in human breast cancer cell lines. Mol Carcinogen. 2001;32:111-7.
49. Pathi SP, Lin DDW, Dorvee JR, Estroff LA, Fischbach C. Hydroxyapatite nanoparticle-containing scaffolds for the study of breast cancer bone metastasis. Biomaterials. 2011;32:5112-22.
50. Meena R, Kesari KK, Rani M, Paulraj R. Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human breast cancer cells (MCF-7). J Nanopart Res. 2012;14:712.
51. Andronescu E, Ficai M, Voicu G, Ficai D, Maganu M, Ficai A. Synthesis and characterization of collagen/hydroxyapatite: Magnetite composite material for bone cancer treatment. J Mater Sci: Mater Med. 2010;21:2237-42.
52. Luo Y, Ling Y, Guo W, Pang J, Liu W, Fang Y, Wen X, Wei K, Gao X. Docetaxel loaded oleic acidcoated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release. 2010;147:278-88.
53. Shen G, Cai C, Yang J. Fabrication of an electrochemical immunosensor based on a gold–hydroxyapatite nanocomposite–chitosan film. Electro Acta. 2011;56:8272-7.
54. Jee JP, Na JH, Lee S, Kim SH, Choi K. Cancer targeting strategies in nanomedicine: Design and application of chitosan nanoparticles. Curr Opin Solid St M. 2012;16:333-42.
55. Abe T, Sakane M, Ikoma T, Kobayashi M, Nakamura S, Ochiai N. Intraosseous delivery of paclitaxel- loaded hydroxyapatite-alginate composite beads delaying paralysis caused by metastatic spine cancer in rats. J Neurosurg. 2008;9:502-10.
56. Andronescu E, Ficai A, Georgiana M, Mitran V, Sonmez M, Ficai D, Ion R, Cimpean A. Collagenhydroxyapatite/ cisplatin drug delivery systems for locoregional treatment of bone cancer. Technol Cancer Res T. 2013;12:275-84.
57. Lee JS, Tung CH. Osteocalcin biomimic recognizes bone hydroxyapatite. Chem Biol Chem. 2011;12:1669-73.
58. Allen C, Han J, Yu Y, Maysinger D, Eisenberg A. Polycaprolactone-b-poly(ethylene oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone. J Control Release. 2000;63:275-86.
59. Morral-Ruíz G, Melgar-Lesmes P, Solans C, García-Celma MJ. Multifunctional polyurethane–urea nanoparticles to target and arrest inflamed vascular environment: A potential tool for cancer therapy and diagnosis. J Control Release. 2013;171:163-71.
60. Saravanabhavan SS, Dharmalingam S. Fabrication of polysulphone/hydroxyapatite nanofiber composite implant and evaluation of their in vitro bioactivity and biocompatibility towards the postsurgical therapy of gastric cancer. Chem Eng J. 2013;234:380-8.
61. Image Source. Available from: http://www.imagesource.com/.
62. Orive G, Ali OA, Anitua E, Pedraz JL, Emerich DF. Biomaterial-based technologies for brain anticancer therapeutics and imaging. Biochim Biophys Acta. 2010;1806:96-107.
63. Restifo N, Dudley M, Rosenberg S. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nature Rev Immun. 2012;12:269-81.
64. Rodriguez-Ruiz I, Delgado-Lopez JM, Duran-Olivencia MA, Iafisco M, Tampieri A, Colangelo D, Prat M, Gomez-Morales J. pH-responsive delivery of doxorubicin from citrate−apatite nanocrystals with tailored carbonate content. Langmuir. 2013;29:8213−21.
65. Kamrava M, Bernstein MB, Camphausen K, Hodge JW. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: The Three Musketeers or just another quixotic combination? Mol BioSyst. 2009;5:1262-70.
66. Malmberg P, Nygren H. Methods for the analysis of the composition of bone tissue, with a focus on imaging mass spectrometry (TOF-SIMS). Proteomics. 2008;8:3755-62.
67. Batchelar DL, Davidson MTM, Dabrowski W, Cunningham IA. Bone-composition imaging using coherent-scatter computed tomography: Assessing bone health beyond bone mineral density. Med Phys. 2006;33:904-15.
68. Legeros RZ. Crystallographic studies of the carbonate substitution in the apatite structure [dissertation]: New York (NY): New York University; 1967.
69. de Groot K. Ceramics of calcium phosphates: preparation and properties. In: Bioceramics of calcium phosphate. Boca Raton, CRC Press; 1983.
70. Holmes RE. Bone regeneration within a coralline hydroxyapatite implant. Plast Reconstr Surg. 1979;63:626-33.
71. Wang Y, Zhang S, Wei K, Zhao N, Chen J, Wang X. Hydrothermal synthesis of hydroxyapatite nanopowders using cationic surfactant as a template. Mater Lett. 2006;60:1484-7.
72. Jarcho M. Calcium phosphate ceramics as hard tissue prosthetics. Clin Orthopaed. 1981;157: 259-78.
73. Pramanik S, Agarwal AK, Rai KN, Garg A. Development of high strength hydroxyapatite by solidstate- sintering process. Ceram Int. 2007;33:419.
74. Ashuri M, Moztarzadeh F, Nezafati N, Ansari Hamedani A, Tahriri M. Development of a composite based on hydroxyapatite and magnesium and zinc containing sol-gel-derived bioactive glass for bone substitute applications. Mater Sci Eng C. 2012;32:2330-9.
75. Liu Y, Hou D, Wang G. A simple wet chemical synthesis and characterization of hydroxyapatite nanorods. Mater Chem Phys. 2004;86:69-73.
76. Hsieh MF, Perng LH, Chin TS, Perng HG. Phase purity of sol-gel-derived hydroxyapatite ceramic. Biomaterials. 2001;22:2601-7.
77. Saber-Samandari S, Saber-Samandari S, Nezafati N, Yahya K. Efficient removal of lead (II) ions and methylene blue from aqueous solution using chitosan/Fe-hydroxyapatite nanocomposite beads. J Environ Manage. 2014;146:481-90.
78. Hesaraki S, Moztarzadeh F, Nemati R, Nezafati N. Preparation and characterization of calcium sulfate- biomimetic apatite nanocomposites for controlled release of antibiotics. J Biomed Mater Res B. 2009;91B:651-61.
79. Bohner M. Physical and chemical aspects of calcium phosphates used in spinal surgery. Eur Spine J. 2001;10:S114-21.
80. Li SH, de Wijn JR, Layrolle P, de Groot K. Synthesis of macroporous hydroxyapatite scaffolds for bone tissue engineering. J Biomed Mater Res B. 2002;61:109-20.
81. Hsieh MF, Perng LH, Chin TS, Perng HG. Phase purity of sol-gel-derived hydroxyapatite ceramic. Biomaterials 2001;22:2601-7.
82. Saber-Samandari S, Saber-Samandari S, Nezafati N, Yahya K. Efficient removal of lead (II) ions and methylene blue from aqueous solution using chitosan/Fe-hydroxyapatite nanocomposite beads. J Environ Manage. 2014;146:481-90.
83. Hesaraki S, Moztarzadeh F, Nemati R, Nezafati N. Preparation and characterization of calcium sulfate- biomimetic apatite nanocomposites for controlled release of antibiotics. J Biomed Mater Res B. 2009;91B:651-61.
84. Bohner M. Physical and chemical aspects of calcium phosphates used in spinal surgery. Eur Spine J. 2001;10:S114-S21.
85. Li SH, de Wijn JR, Layrolle P, deGroot K. Synthesis of macroporous hydroxyapatite scaffolds for bone tissue engineering. J Biomed Mater Res B. 2002;61:109-20.
86. Chen F, Huang P, Zhu YJ, Wu J, Zhang CL, Cui DX. The photoluminescence, drug delivery and imaging properties of multifunctional Eu3+/Gd3+ dual-doped hydroxyapatite nanorods. Biomaterials. 2011;32:9031-9.
87. Chen F, Tang QL, Zhu YJ, Wang KW, Zhang ML, Zhai WY, Chang J. Hydroxyapatite nanorods/ poly(vinyl pyrolidone) composite nanofibers, arrays and three-dimensional fabrics: Electrospun preparation and transformation to hydroxyapatite nanostructures. Acta Biomater. 2010;6:3013-20.
88. Sun Q, Lou JT, Kang F, Chen JF, Wang JX. Facile preparation of hydroxyapatite nanotubes assisted by needle-like calcium carbonate. Powder Technol. 2014;261:49-54.
89. Viswanath B, Ravishankar N. Controlled synthesis of plate-shaped hydroxyapatite and implications for the morphology of the apatite phase in bone. Biomaterials. 2008;29:4855-63.
90. Saber-Samandari S, Gross KA. Micromechanical properties of single crystal hydroxyapatite by nanoindentation. Acta Biomater. 2009;5:2206-12.
91. Kim HW, Knowles JC, Kim HE. Hydroxyapatite porous scaffold engineered with biological polymer hybrid coating for antibiotic vancomycin release. J Mater Sci: Mater Med. 2005;16:189-95.
92. Kokubo T. Bioceramics and their clinical applications. Tokyo: Woodhead Publishing; 2008.
93. Roese PB, Amico SC, Júnior WK. Thermal and microestructural characterization of epoxy-infiltrated hydroxyapatite composite. Mater Res. 2009;12:107-11.
94. Fowler BO. Infrared studies of apatites. II. Preparation of normal and isotopically substituted calcium, strontium and barium hydroxyapatites and spectra-structure-composition correlations. Inorg Chem. 1974;13:207-14.
95. Gross KA, Young CJ, Beck MA, Keebaugh EW, Bronts TJ, Saber-Samandari S, Riley DP. Characterization and dissolution of functionalized amorphous calcium phosphate biolayers using single-splat technology. Acta Biomater. 2011;7:2270-5.
96. Elliott JC. The crystallographic structure of dental enamel and related apatites [dissertation]. London, UK; University of London; 1964.
97. Beevers CA, McIntyre DB. The atomic structure of fluorapatite and its relation to that of tooth and bone mineral. Mineral Mag. 1956;27:254-9.
98. Zhou C, Ye X, Fan Y, Ma L, Tan Y. Biomimetic fabrication of a three-level hierarchical calcium phosphate/collagen/hydroxyapatite scaffold for bone tissue engineering. Biofabrication 2014;6:035013.
99. Chen C, Huang Z, Yuan W, Li J, Cheng X, Chi R. Pressure effecting on morphology of hydroxyapatite crystals in homogeneous system. Cryst Eng Comm. 2011;13:1632-7.
100. Im O, Li J, Wang M, Zhang LG, Keidar M. Biomimetic three-dimensional nanocrystalline hydroxyapatite and magnetically synthesized single-walled carbon nanotube chitosan nanocomposite for bone regeneration. Int J Nanomed. 2012;7:2087-99.
101. Saber-Samandari S, Saber-Samandari S, Gazi M. Cellulose-graft-polyacrylamide/hydroxyapatite composite hydrogel with possible application in removal of Cu (II) ions. Reac Func Polym. 2013;73:1523-30.
102. Zhang Y, Yao N, Wang F, Lia W, Jiang S. A novelin situ self foaming method for the synthesis of porous calcium metaphosphate biomaterials. RSC Adv. 2014;4:60007-16.
103. Saber-Samandari S, Alamara K, Saber-Samandari S, Gross KA. Micro-Raman spectroscopy shows how the coating process affects the characteristics of hydroxylapatite. Acta Biomater. 2013;9:9538-46.
104. Saber-Samandari S, Berndt CC, Gross KA. Selection of the implant and coating materials for optimized performance by means of nanoindentation. Acta Biomater. 2011;7:874-81.
105. Loo SCJ, Moore T, Banik B, Alexis F. Biomedical applications of hydroxyapatite nanoparticles. Curr Pharm Biotechnol. 2010;11:333-42.
106. Nayar S, Sinha MK, Basu D, Sinha A. Synthesis and sintering of biomimetic hydroxyapatite nanoparticles for biomedical applications. J Mater Sci: Mater Med. 2006;17:1063-8.
107. Saber-Samandari S, Gross KA. Amorphous calcium phosphate offers improved crack resistance: A design feature from nature? Acta Biomater. 2011;7:4235-41.
108. Saber-Samandari S, Gross KA. The use of thermal printing to control the properties of calcium phosphate deposits. Biomaterials. 2010;31:6386-93.
109. Saber-Samandari S, Gross KA. Contact nanofatigue shows crack growth in amorphous calcium phosphate on Ti, Co-Cr and stainless steel. Acta Biomater. 2013;9:5788-94.
110. Sadat-Shojai M, Khorasani MT, Dinpanah-Khoshdargi E, Jamshidi A. Synthesis methods for nanosized hydroxyapatite with diverse structures. Acta Biomater. 2013;9:7591-621.
111. Palanivelu R, Kumar AR. Synthesis, characterization, in vitro anti-proliferative and hemolytic activity of hydroxyapatite. Spectrochim Acta A. 2014;127:434-8.
112. des Rieux A, Fievez V, Garinot M, Schneider Y, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release. 2006;116:1-27.
113. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci. 2002;6:319-27.
114. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1-20.
115. Luo D, Saltzman W. Synthetic DNA delivery systems. Nature Biotechnol. 2000;18:33-7.
116. Prego C, García M, Torres D, Alonso MJ. Transmucosal macromolecular drug delivery. J Control Release. 2005;101:151-62.
117. Gorbunoff MJ, Timasheff SN. The interaction of proteins with hydroxyapatite: III. Mechanism. Anal Biochem. 1984;136:440-5.
118. Victor S, Kumar TS. Tailoring calcium-deficient hydroxyapatite nanocarriers for enhanced release of antibiotics. J Biomed Nanotechnol. 2008;4:203-9.
119. Cheng X, Kuhn L. Chemotherapy drug delivery from calcium phosphate nanoparticles. Int J Nanomed. 2007;2:667-74.
120. YuLing J, Loo SC, Phung NT, Boey F, Ma J. Controlled size and morphology of EDTMP-doped hydroxyapatite nanoparticles as model for 153Samarium-EDTMP doping. J Mater Sci: Mater Med. 2008;19:2993-3003.
121. Goyal A, Khatri K, Mishra N, Mehta A, Vaidya B, Tiwari S, Paliwal R, Paliwal S, Vyas SP. Development of self-assembled nanoceramic carrier construct(s) for vaccine delivery. J Biomater Appl. 2009;24:65-84.
122. Li J, Yin Y, Yao F, Zhang L, Yao K. Effect of nano- and micro-hydroxyapatite/chitosan-gelatin network film on human gastric cancer cells. Mater Lett. 2008;62:3220-3.
123. Venkatesan P, Puvvada N, Dash R, Kumar BNP, Sarkar D, Azab B, Pathak A, Kundu SC, Fisher PB, Mandal M. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials. 2011;32:3794-806.
124. Yuan Y, Liu C, Qian J, Wang J, Zhang Y. Size-mediated cytotoxicity and apoptosis of hydroxyapatite nanoparticles in human hepatoma HepG2 cells. Biomaterials. 2010;31:730-40.
125. Bohner M, van Lenthe GH, Grünenfelder S, Hirsiger W, Evison R, Müller R. Synthesis and characterization of porous-b-tricalcium phosphate blocks. Biomaterials. 2005;26:6099-105.
126. Bohner M, Lemaitre J, Merckle HP, Gander B. Control of gentamicin release from a calcium phosphate admixed poly(acrylic acid). J Pharm Sci. 2000;89:1262-70.
127. Otsuka M, Nakahigashi Y, Matsuda Y, Fox JL, Higuchi WI, Sugiyama Y. Effect of geometrical cement size on in vitro indomethacin release from self-setting apatite cement. J Control Release. 1998;52:281-9.
128. Lemaire V, Bélair J, Hildgen P. Structural modeling of drug release from biodegradable porous matrices based on a combined diffusion/erosion process. Int J Pharm. 2003;258:95-107.
129. Sant S, Nadeau V, Hildgen P. Effect of porosity on the release kinetics of propafenone-loaded PEGg- PLA nanoparticles. J Control Release. 2005;107:203-14.
130. Takeyama H, Mohri N, Mizuno I, Akamo Y, Sawai H. Treatment of peritoneal carcinomatosis using carboplatin-loaded hydroxyapatite particles. Anticancer Res. 2006;26:4603-6.
131. Ito N, Kamitakahara M, Ioku K. Preparation and evaluation of spherical porous granules of octacalcium phosphate/hydroxyapatite as drug carriers in bone cancer treatment. Mater Lett. 2014;120:94-6.
132. Itokazu M, Kumazawa S, Wada E, Wenyi Y. Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice. Cancer Lett. 1996;107:11-8.
133. Itokazu M, Esaki M, Yamamoto K, Tanemori T, Kasai T. Local drug delivery system using ceramics: Vacuum method for impregnating a chemotherapeutic agent into a porous hydroxyapatite block. J Mater Sci: Mater M. 1999;10:249-52.
134. Lopez T, Ortiz E, Alexander-Katz R, Odriozola JA, Quintana P, Gonzalez RD, Lottici PP, Marino IG. The effect of water on particle size, porosity and the rate of drug release from implanted titania reservoirs. J Biomed Mater Res B. 2010;93B:401-6.
135. Slosarczyk A, Szymura-Oleksiak J, Mycek B. The kinetics of pentoxifylline release from drug-loaded hydroxyapatite implants. Biomaterials. 2000;21:1215-21.
136. Bohner M, lemaıtre J, van Landuyt P, Zambelli PY, Merkle HP, Gander B. Gentamicin- loaded hydraulic calcium phosphate bone cement as antibiotic delivery system. J Pharm Sci. 1997;86:565-72.
137. Barroug A, Kuhn LT, Gerstenfeld LC, Glimcher MJ. Interactions of cisplatin with calcium phosphate nanoparticles: In vitro controlled adsorption and release. J Orthop Res. 2004;22:703-8.
138. Legeros RZ, Trautz OR, Legeros JP, Klein E, Shirra WP. Apatite crystallites: Effects of carbonate on morphology. Science. 1967;155:1409-11.
139. Rey C, Combes C, Drouet C, Sfihi H, Barroug A. Physicochemical properties of nanocrystalline apatites: Implications for biominerals and biomaterials. Mater Sci Eng C. 2007;27:198-205.
140. Beijnen JH, van der Houwen OAGJ, Underberg WJM. Aspects of the degradation kinetics of doxorubicin in aqueous solution. Int J Pharm. 1986;32:123-31.
141. Palazzo B, Iafisco M, Laforgia M, Margiotta N, Natile G, Bianchi CL, Walsh D, Mann S, Roveri N. Biomimetic hydroxyapatite—drug nanocrystals as potential bone substitutes with antitumor drug delivery properties. Adv Funct Mater. 2007;17:2180-8.
142. Cho K, Wang X, Nie S, Chen Z, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310-6.
143. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189-207.
144. Kim J, Piao Y, Hyeon T. Multifunctional nanostructured materials for multimodal imaging, and simultaneous imaging and therapy. Chem Soc Rev. 2009;38:372-90.
145. Kwona S, Singh RK, Kim TH, Patel KD, Kim JJ, Chrzanowski W, Kim HW. Luminescent mesoporous nanoreservoirs for the effective loading and intracellular delivery of therapeutic drugs. Acta Biomater. 2014;10:1431-42.
146. Guo Y, Shi DL, Cho H, Dong ZY, Kulkarni A, Pauletti GM, Wang W, Lian J, Liu W, Ren L, Zhang Q, Liu G, Huth C, Wang L, Ewing RC. In vivo imaging and drug storage by quantum-dot-conjugated carbon nanotubes. Adv Funct Mater Let. 2008;18:2489-97.
147. You J, Zhang GD, Li C. Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. ACS Nano. 2010;4:1033-41.
148. Tang S, Huang XQ, Chen XL, Zheng NF. Hollow mesoporous zirconia nanocapsules for drug delivery. Adv Funct Mater. 2010;20:2442-7.
149. Lin MM, Kim H-H, Kim H, Dobson J, Kim DK. Surface activation and targeting strategies of superparamagnetic iron oxide nanoparticles in cancer-oriented diagnosis and therapy. Nanomedicine (London). 2010;5:109-33.
150. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2:750-63.
151. Bacha RA, Fiallo MML, Sharrock P. Release of anthracyclines adsorbed on copper-treated hydroxylapatites. J Biomed Mater Res B. 2002;70B:103-5.
152. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 2003;66:1207-18.
153. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy. Adv Drug Delivery Rev. 2011;63:24-46.
154. Chen F, Li C, Zhu YJ, Zhao XY, Lub BQ, Wub J. Magnetic nanocomposite of hydroxyapatite ultrathin nanosheets/Fe3O4 nanoparticles: Microwave-assisted rapid synthesis and application in pHresponsive drug release. Biomater Sci. 2013;1:1074-81.
155. Gu L, He X, Wu Z. Mesoporous Fe3O4/hydroxyapatite composite for targeted drug delivery. Mater Res Bull. 2014;59:65-8.
156. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today. 2007;2:22-32.
157. Kim J, Kim HS, Lee N, Kim T, Kim H, Yu T, Song IC, Moon WK, Hyeon T. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew Chem Int Edit. 2008;47:8438-41.
158. Zumbuehl A, Jeannerat D, Martin SE, Sohrmann M, Stano P, Vigassy T, Clark DD, Hussey SL, Peter M, Peterson BR, Pretsch E, Walde P, Carreira EM. An amphotericin b–fluorescein conjugate as a powerful probe for biochemical studies of the membrane. Angew Chem Int Ed. 2004;43:5181-5.
159. Gao X, Nie S. Molecular profiling of single cells and tissue specimens with quantum dots. Trends Biotechnol. 2003;21:371-3.
160. Yong KT, Ding H, Roy I, Law WC, Bergey EJ, Maitra A, Prasad PN. Imaging pancreatic cancer using bioconjugated InP quantum dots. ACS Nano. 2009;3:502-10.
161. Lin YS, Wu SH, Hung Y, Chou YH, Chang C, Lin ML, Tsai CP, Mou CY. Multifunctional composite nanoparticles: Magnetic, luminescent, and mesoporous. Chem Mater. 2006;18:5170-2.
162. Wang W, Shi DL, Lian J, Guo Y, Liu GK, Wang LM, Ewing RC. Luminescent hydroxylapatite nanoparticles by surface functionalization. Appl Phys Lett. 2006;89:183106.
163. Li Z, Liu Z, Yin M, Yang X, Yuan Q, Ren J, Qu X. Aptamer-capped multifunctional mesoporous strontium hydroxyapatite nanovehicle for cancer-cell-responsive drug delivery and imaging. Biomacromolecules. 2012;13:4257-63.
164. Watanabe K, Nishio Y, Makiura R, Nakahira A, Kojima C. Paclitaxel-loaded hydroxyapatite/collagen hybrid gels as drug delivery systems for metastatic cancer cells. Int J Pharm. 2013;446:81-6.
165. Kojima C, Watanabe K, Nagayasu T, Nishio Y, Makiura R, Nakahira A. Preparation of hydroxyapatite- decorated poly(lactide-co-glycolide) microspheres for paclitaxel delivery. J Nanopart Res. 2013;15:2098-108.
166. Bach LG, Islam MR, Vo TS, Kim SK, Lim KT. Poly(allyl methacrylate) functionalized hydroxyapatite nanocrystals via the combination of surface-initiated RAFT polymerization and thiol–ene protocol: A potential anticancer drug nanocarrier. J Colloid Interf Sci. 2013;394:132-40.
167. Letic-Gavrilovic A, Piattelli A, Abe K. Nerve growth factor β (NGF β) delivery via a collagen/ hydroxyapatite (Col/HAp) composite and its effects on new bone growth. J Mater Sci: Mater M. 2003;14:95-102.
168. Chen J, Luo Y, Hong L, Ling Y, Pang J, Fang Y, Wei K, Gao X. Synthesis, characterization and osteoconductivity properties of bone fillers based on alendronate-loaded poly(e-caprolactone)/hydroxyapatite microspheres. J Mater Sci: Mater M. 2011;22:547-55.
169. Yannas IV. Classes of materials used in medicine: Natural materials. San Diego: Elsevier Academic Press; 2004.
170. Nigam R, Mahanta B. An overview of various biomimetic scaffolds: Challenges and applications in tissue engineering. J Tissue Sci Eng. 2014;5:137-41.
171. Ozbas-Turan S, Aral C, Kabasakal L, Keyer-Uysal M, Akbuga J. Co-encapsulation of two plasmids in chitosan microspheres as a non-viral gene delivery vehicle. J Pharm Pharmaceut Sci. 2003;6:27-32.
172. Bhattarai N, Ramay HR, Chou SH, Zhang M. Chitosan and lactic acid-grafted chitosan nanoparticles as carriers for prolonged drug delivery. Int J Nanomed. 2006;1:181-7.
173. Zhang H, Neau H. In vitro degradation of chitosan by a commercial enzyme preparation: Effect of molecular weight and degree of deacetylation. Biomaterials. 2001;22:1653-8.
174. Zheng F, Shi XW, Yang GF, Gong LL, Yuan HY. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: Results of an in vitro and in vivo study. Life Sci. 2007;80: 388-96.
175. Pan Y, Li YJ, Zhao HY, Zheng JM, Xu H. Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm. 2002;249: 139-47.
176. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res. 1994;11:1186-9.
177. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY. Chitosan-DNA nanoparticles as gene carriers: Synthesis, characterization and transfection efficacy. J Control Release. 2001;70:399-421.
178. Murata Y, Tsumoto K, Kofuji K, Kawashima S. Effects of natural polysaccharide addition on drug release from calcium-induced alginate gel beads. Chem Pharm Bull. 2003;51:218-20.
179. Liang YH, Liu CL, Liao SH, Lin YY, Tang HW, Liu SY, Lai IR, Wu KCW. Cosynthesis of cargoloaded hydroxyapatite/alginate core−shell nanoparticles (HAP@Alg) as ph-responsive nanovehicles by a pregel method. ACS Appl Mater Interfaces. 2012;4:6720−7.
180. Chai F, Abdelkarim M, Laurent T, Tabary N, Degoutin S, Simon N, Peters F, Blanchemain N, Martel B, Hildebrand HF. Poly-cyclodextrin functionalized porous bioceramics for local chemotherapy and anticancer bone reconstruction. J Biomed Mater Res B. 2013;102:1130-9.
181. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98:2045-76.
182. Rao PN, Smith ML, Pathak S, Howard RA, Bear JL. Rhodium (II) butyrate: A potential anticancer drug with cell cycle phase-specific effects in HeLa cells. J Nat Cancer Inst. 1980;64:905-12.
183. Lepretre S, Chai F, Hornez JC, Vermet G, Neut C, Descamps M, Hildebrand HF, Martel B. Prolonged local antibiotics delivery from hydroxyapatite functionalised with cyclodextrin polymers. Biomaterials. 2009;30:6086-93.
184. Gelse K, Poschl E, Aigner T. Collagens—structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003;55:1531-46.
185. Wallace DG, Rosenblatt J. Collagen gel systems for sustained delivery and tissue engineering. Adv Drug Deliv Rev. 2003;55:1631-49.
186. Friess W. Collagen-biomaterial for drug delivery. Eur J Pharm Biopharm. 1998;45:113-36.
187. Sundar SS, Sangeetha D. Fabrication and evaluation of electrospun collagen/poly(N-isopropyl acrylamide)/ chitosan mat as blood-contacting biomaterials for drug delivery. J Mater Sci: Mater M. 2012;23:1421-30.
188. Matthews JA, Boland ED, Wnek GE, Simpson DG, Bowlin GL. Electrospinning of collagen type II: A feasibility study. J Bioact Compat Polym. 2003;18:125-34.
189. Saito T, Tabata Y. Hypoxia-induced angiogenesis is increased by the controlled release of deferoxiamine from gelatin hydrogels. Acta Biomater. 2014;10:3641-9.
190. Santoro M, Tatara AM, Mikos AG. Gelatin carriers for drug and cell delivery in tissue engineering. J Control Release. 2014;190:210-8.
191. Elzoghby AO. Gelatin-based nanoparticles as drug and gene delivery systems: Reviewing three decades of research. J Control Release. 2013;172:1075-91.
192. Chang KH, Liao HT, Chen JP. Preparation and characterization of gelatin/hyaluronic acid cryogels for adipose tissue engineering: In vitro and in vivo studies. Acta Biomater. 2013;9:9012-26.
193. Gaowa A, Horibe T, Kohno M, Sato K, Harada H, Hiraoka M, Tabata Y, Kawakami K. Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled release and enhancement of antitumor activity in vivo. J Control Release. 2014;176:1-7.
194. Pok S, Myers JD, Madihally SV, Jacot JG. A multilayered scaffold of a chitosan and gelatin hydrogel supported by a PCL core for cardiac tissue engineering. Acta Biomater. 2013;9:5630-42.
195. Dou XC, Zhu XP, Zhou J, Cai HQ, Tang J. Minocycline-released hydroxyapatite–gelatin nanocomposite and its cytocompatibility in vitro. Biomed Mater. 2011;6:025002.
196. Yan SQ, Zhang Q, Wang JN, Liu Y, Lu SZ, Li MZ, Kaplan DL. Silk fibroin/chondroitin sulfate/hyaluronic acid ternary scaffolds for dermal tissue reconstruction. Acta Biomater. 2013;9:6771-82.
197. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes. Physiol Rev. 1991;71:481-539.
198. Zou XH, Jiang YZ, Zhang GR, Jin HM, Hieu NTM. Specific interactions between human fibroblasts and particular chondroitin sulfate molecules for wound healing. Acta Biomater. 2009;5:1588-95.
199. Lim JJ, Hammoudi TM, Bratt-Leal AM, Hamilton SK, Kepple KL. Development of nano- and microscale chondroitin sulfate particles for controlled growth factor delivery. Acta Biomater. 2011;7:986-95.
200. Zarnescu O, Moldovan L, Trif M, Moisei M, Craciunescu O. Light and electron microscopy characterization of a collagen–liposome-entrapped chondroitin sulfate composite as intra-articular drug delivery system. J Control Release. 2011;152:1-132.
201. Xu H, Yan Y, Li S. PDLLA/chondroitin sulfate/chitosan/NGF conduits for peripheral nerve regeneration. Biomaterials. 2011;32:4506-16.
202. Guo Y, Shi X, Fang Q, Zhang J, Fang H, Jia W, Yang G, Yang L. Facile preparation of hydroxyapatite– chondroitin sulfate hybrid mesoporous microrods for controlled and sustained release of anti tumor drugs. Mater Lett. 2014;125:111-5.
203. Stubbs M, McSheehy PMJ, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 2000;6:15-9.
204. Wang Y, Kim HJ, Vunjak-Novakovic G, Kaplan DL. Stem cell-based tissue engineering with silk biomaterials. Biomaterials. 2006;27:6064-82.
205. Vollrath F, Knight DP. Liquid crystalline spinning of spider silk. Nature. 2001;410:541-8.
206. Altman GH, Diaz F, Jakuba C, Calabro T, Horan RL, Chen JS, Lu H, Richmond J, Kaplan DL. Silkbased biomaterials. Biomaterials. 2003;24:401-16.
207. Vollrath F. Biology of spider silk. Int J Biol Macromol. 1999;24:81-8.
208. Gosline JM, Guerette PA, Ortlepp CS, Savage KN. The mechanical design of spider silks: From fibroin sequence to mechanical function. J Exp Biol. 1999;202:3295-303.
209. Hayden RS, Vollrath M, Kaplan DL. Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk–hydroxyapatite films. Acta Biomater. 2014;10:486-93.
210. Wang X, Yucel T, Lu Q, Hu X, Kaplan DL. Silk nanospheres and microspheres from silk/pva blend films for drug delivery. Biomaterials. 2010;31:1025-35.
211. Fu YC, Fud TF, Wang HJ, Lin CW, Lee GH, Wu SC, Wang CK. Aspartic acid-based modified PLGA– PEG nanoparticles for bone targeting: In vitro and in vivo evaluation. Acta Biomater. 2014;10:4583-96.
212. Rong T, Yala L, Fan TM, Cheng J. The formulation of aptamer-coated paclitaxel–polylactide nanoconjugates and their targeting to cancer cells. Biomaterials. 2010;31:3043-53.
213. Liu D, Liu S, Jing X, Li X, Li W, Huang Y. Necrosis of cervical carcinoma by dichloroacetate released from electrospun polylactide mats. Biomaterials. 2012;33:4362-9.
214. Tao W, Zeng X, Liu T, Wang Z, Xiong Q, Ouyang C, Huang L, Mei L. Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy. Acta Biomater. 2013;9:8910-20.
215. Dong Y, Feng SS. In vitro and in vivo evaluation of methoxy polyethylene glycol–polylactide (MPEG–PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials. 2007;28:4154-60.
216. Li D, Sun H, Ding J, Tang Z, Zhang Y, Xu W, Zhuang X, Chen X. Polymeric topology and composition constrained polyether–polyester micelles for directional antitumor drug delivery. Acta Biomater. 2013;9:8875-84.
217. Wang JL, Sun J, Chen Q, Gao Y, Li L, Li H, Leng DL, Wang YJ, Sun YH, Jing YK, Wang SL, He ZG. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials. 2012;33:6877-88.
218. Lin Y, Li Y, Ooi C. 5-Fluorouracil encapsulated HA/PLGA composite microspheres for cancer therapy. J Mater Sci: Mater Med. 2012;23:2453-60.
219. Zheng F, Wang S, Shen M, Zhub M, Shi X. Antitumor efficacy of doxorubicin-loaded electrospun nano-hydroxyapatite–poly(lactic-co-glycolic acid) composite nanofibers. Polym Chem. 2013;4: 933-41.
220. Pelss J, Loca D, Berzina-Cimdina L, Locs J, Lakevics V. Release of anticancer drug doxorubicin from biodegradable polymer coated porous hydroxyapatite scaffolds. Adv Mater Res. 2011;284-286: 1770-3.
221. Ta HT, Dass CR, Larson I, Choong PF, Dunstan DE. A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. Biomaterials. 2009;27:4815-23.
222. Venkatasubbu GD, Ramasamy S, Avadhani GS, Ramakrishnan V, Kumar J. Surface modification and paclitaxel drug delivery of folic acid modified polyethylene glycol functionalized hydroxyapatite nanoparticles. Powder Technol. 2013;235:437-42.
223. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliver Rev. 2000;41:147-62.
224. Lu YJ, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliver Rev. 2002;54:675-93.